Literature DB >> 9351063

Cyclosporin nephrotoxicity following cardiac transplantation.

R G Woolfson, G H Neild.   

Abstract

The greatest change in GFR in response to treatment with cyclosporin occurs in the first 3-6 months and the magnitude of the decrement in the first year (or perhaps the first few months) appears to be a vital indicator of future problems. However, the apparent stabilization of renal function, particularly when monitored only by plasma creatinine, can conceal progressive tubulointerstitial injury, and increasing proteinuria is an ominous sign. Although lower doses of cyclosporin and careful monitoring of renal function may be helpful, there is at present no pharmacological intervention to protect or reverse the reduction in GFR that occurs. We believe that the vascular lesion induced by cyclosporin is fundamental, with early and initially reversible cyclosporin-induced vasospasm leading to progressive vascular damage with activation of endothelial cells and increased platelet interactions. Amongst other determinants, the renal response to this vasculopathy will depend on the balance between the presence of vasoactive factors with the vasoconstrictors promoting interstitial fibrosis and the vasodilators inhibiting proliferation. It is likely that the kidneys of heart-transplant recipients are chronically ischaemic and as a consequence their renin-angiotensin systems massively activated, which may further sensitize their kidneys to cyclosporin. Overproduction of angiotensin II, associated with the DD ACE genotype, has already been associated with poor prognosis in diabetic and IgA nephropathy. It is interesting to speculate that this ACE genotype, which is associated with a poor outcome in non-ischaemic heart disease can influence renal sensitivity to cyclosporin and predict the development of morphological injury. Extension of these experimental findings into the clinical arena with a placebo-controlled trial of early introduction of ACE inhibitor therapy in recipients of cardiac transplants would be timely.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9351063     DOI: 10.1093/ndt/12.10.2054

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  9 in total

Review 1.  The challenge of renal function in heart transplant children.

Authors:  Sylvie Di Filippo; Pierre Cochat; André Bozio
Journal:  Pediatr Nephrol       Date:  2006-08-24       Impact factor: 3.714

2.  Sirolimus-based calcineurin inhibitor withdrawal immunosuppressive regimen in kidney transplantation: a single center experience.

Authors:  Sameer M Alarrayed; Amgad E El-Agroudy; Ahmad S Alarrayed; Sumaya M Al Ghareeb; Taysir S Garadah; Salah Y El-Sharqawi; Ali H Al-Aradi; Balaji G Dandi; Sadiq Abdulla
Journal:  Clin Exp Nephrol       Date:  2010-03-16       Impact factor: 2.801

3.  Cyclosporine exacerbates ketamine toxicity in zebrafish: Mechanistic studies on drug-drug interaction.

Authors:  Bonnie L Robinson; Melanie Dumas; Syed F Ali; Merle G Paule; Qiang Gu; Jyotshna Kanungo
Journal:  J Appl Toxicol       Date:  2017-06-01       Impact factor: 3.446

Review 4.  Immunosuppressive therapy in older cardiac transplant patients.

Authors:  Arezu Zejnab Aliabadi; Andreas Oliver Zuckermann; Michael Grimm
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

5.  Long-term renal function in heart transplant children on cyclosporine treatment.

Authors:  Luca Dello Strologo; Francesco Parisi; Antonia Legato; Claudia Pontesilli; Anna Pastore; Lucilla Ravà; Alberto E Tozzi; Gianfranco Rizzoni
Journal:  Pediatr Nephrol       Date:  2006-02-21       Impact factor: 3.714

6.  Tacrolimus (FK506): Safety and Applications in Reconstructive Surgery.

Authors:  Thomas H Tung
Journal:  Hand (N Y)       Date:  2009-04-11

Review 7.  Cyclosporine A: Novel concepts in its role in drug-induced gingival overgrowth.

Authors:  Deepa Ponnaiyan; Visakan Jegadeesan
Journal:  Dent Res J (Isfahan)       Date:  2015 Nov-Dec

8.  Alport syndrome: significance of gingival biopsy in the initial diagnosis and periodontal evaluation after renal transplantation.

Authors:  Hilal Uslu Toygar; Okan Toygar; Esra Guzeldemir; Ulkem Cilasun; Ahmet Nacar; Nebil Bal
Journal:  J Appl Oral Sci       Date:  2009 Nov-Dec       Impact factor: 2.698

9.  Efficacy and safety of early tacrolimus conversion to sirolimus after kidney transplantation: Long-term results of a prospective randomized study.

Authors:  A E El-Agroudy; S M Alarrayed; S M Al-Ghareeb; E Farid; H Alhelow; S Abdulla
Journal:  Indian J Nephrol       Date:  2017 Jan-Feb
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.